Syk inhibitors as treatment for allergic rhinitis

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 3, 2008, Pages 461-467

  Masuda, Esteban S ^a   Schmitz, Jochen ^a  

^a RIGEL PHARMACEUTICALS INC   (United States)

Author keywords

Allergic rhinitis; IgE receptor; Kinase inhibitor; Mast cells; Syk

Indexed keywords

2,4 DIAMINOPYRIMIDINE DERIVATIVE; CORTICOSTEROID; FC RECEPTOR; IMMUNOGLOBULIN E; OMALIZUMAB; PLACEBO; PROTEIN KINASE SYK; R 112;

ALLERGIC RHINITIS; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENT; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; MAST CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SYMPTOM;

ANIMALS; ANTI-ALLERGIC AGENTS; ENZYME INHIBITORS; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN E; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN-TYROSINE KINASES; RECEPTORS, IGE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; SIGNAL TRANSDUCTION;

EID: 43049113886     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2007.06.002     Document Type: Article

References (54)

1. Bodtger U., and Linneberg A. Remission of allergic rhinitis: an 8-year observational study. J Allergy Clin Immunol 114 (2004) 1384-1388
2. Crystal-Peters J., Neslusan C., Crown W.H., and Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 109 (2002) 57-62
3. Skoner D.P. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 108 (2001) S2-S8
4. Macglashan Jr. D. IgE and FcεRI regulation. Ann NY Acad Sci 1050 (2005) 73-88
5. Poole J.A., Matangkasombut P., and Rosenwasser L.J. Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy. J Allergy Clin Immunol 115 (2005) S376-S385
6. Galli S.J., Kalesnikoff J., Grimbaldeston M.A., Piliponsky A.M., Williams C.M., and Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 23 (2005) 749-786
7. Church MK, Shute JK, Sampson AP. Mast cell-derived mediators. In: Adkinson FFJ, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER, editors. Middleton's allergy principles and practice, vol. I, 6th ed. Mosby Inc.; 2003. p. 189-212.
8. Gelfand E.W. Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol 114 (2004) S135-S138
9. Plaut M., and Valentine M.D. Clinical practice. Allergic rhinitis. N Engl J Med 353 (2005) 1934-1944
10. Workshops Mot. ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma. Allergy 59 (2004) 373-387
11. Holgate S.T., and Broide D. New targets for allergic rhinitis-a disease of civilization. Nat Rev Drug Discov 2 (2003) 902-914
12. Nelson H.S. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 117 (2006) 1047-1053
13. Simons FER. Antihistamines. In: Adkinson FFJ, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER, editors. Middleton's allergy principles and practice, vol. I, 6th ed. Mosby Inc.; 2003. p. 834-69.
14. Nelson HS. Beta-adrenergic agonists. In: Adkinson FFJ, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER, editors. Middleton's allergy principles and practice, vol. I, 6th ed. Mosby Inc.; 2003. p. 803-21.
15. Haberal I., and Corey J.P. The role of leukotrienes in nasal allergy. Otolaryngol Head Neck Surg 129 (2003) 274-279
16. Barnes P.J. Corticosteroids: the drugs to beat. Eur J Pharmacol 533 (2006) 2-14
17. Sayama K., Diehn M., Matsuda K., Lunderius C., Tsai M., Tam S.Y., et al. Transcriptional response of human mast cells stimulated via the FcεRI and identification of mast cells as a source of IL-11. BMC Immunol 3 (2002) 5
18. Holgate S., Casale T., Wenzel S., Bousquet J., Deniz Y., and Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115 (2005) 459-465
19. Chervinsky P., Casale T., Townley R., Tripathy I., Hedgecock S., Fowler-Taylor A., et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 91 (2003) 160-167
20. Barnes P.J. Novel signal transduction modulators for the treatment of airway diseases. Pharmacol Ther 109 (2006) 238-245
21. Kovarova M., and Rivera J. A molecular understanding of mast cell activation and the promise of anti-allergic therapeutics. Curr Med Chem 11 (2004) 2083-2091
22. Wong B.R., Grossbard E.B., Payan D.G., and Masuda E.S. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 13 (2004) 743-762
23. Wong W.S. Inhibitors of the tyrosine kinase signaling cascade for asthma. Curr Opin Pharmacol 5 (2005) 264-271
24. Gilfillan A.M., and Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 6 (2006) 218-230
25. Kawakami T., and Galli S.J. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2 (2002) 773-786
26. Siraganian R.P. Mast cell signal transduction from the high-affinity IgE receptor. Curr Opin Immunol 15 (2003) 639-646
27. Lowell C.A. Src-family kinases: rheostats of immune cell signaling. Mol Immunol 41 (2004) 631-643
28. Kawakami Y., Kitaura J., Satterthwaite A.B., Kato R.M., Asai K., Hartman S.E., et al. Redundant and opposing functions of two tyrosine kinases, Btk and Lyn, in mast cell activation. J Immunol 165 (2000) 1210-1219
29. Costello P.S., Turner M., Walters A.E., Cunningham C.N., Bauer P.H., Downward J., et al. Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells. Oncogene 13 (1996) 2595-2605
30. Turner M., Schweighoffer E., Colucci F., Di Santo J.P., and Tybulewicz V.L. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today 21 (2000) 148-154
31. Ulanova M., Duta F., Puttagunta L., Schreiber A.D., and Befus A.D. Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis. Expert Opin Ther Targets 9 (2005) 901-921
32. Billadeau D.D., Upshaw J.L., Schoon R.A., Dick C.J., and Leibson P.J. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol 4 (2003) 557-564
33. Zompi S., Hamerman J.A., Ogasawara K., Schweighoffer E., Tybulewicz V.L., Di Santo J.P., et al. NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases. Nat Immunol 4 (2003) 565-572
34. Clark E.A., Shattil S.J., Ginsberg M.H., Bolen J., and Brugge J.S. Regulation of the protein tyrosine kinase pp72syk by platelet agonists and the integrin alpha IIb beta 3. J Biol Chem 269 (1994) 28859-28864
35. Ulanova M., Puttagunta L., Marcet-Palacios M., Duszyk M., Steinhoff U., Duta F., et al. Syk tyrosine kinase participates in beta1-integrin signaling and inflammatory responses in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 288 (2005) L497-L507
36. Woodside D.G., Obergfell A., Talapatra A., Calderwood D.A., Shattil S.J., and Ginsberg M.H. The N-terminal SH2 domains of Syk and ZAP-70 mediate phosphotyrosine-independent binding to integrin beta cytoplasmic domains. J Biol Chem 277 (2002) 39401-39408
37. Bulanova E., Budagian V., Pohl T., Krause H., Durkop H., Paus R., et al. The IL-15R alpha chain signals through association with Syk in human B cells. J Immunol 167 (2001) 6292-6302
38. Cha H.S., Boyle D.L., Inoue T., Schoot R., Tak P.P., Pine P., et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 317 (2006) 571-578
39. Yanagi S., Inatome R., Takano T., and Yamamura H. Syk expression and novel function in a wide variety of tissues. Biochem Biophys Res Commun 288 (2001) 495-498
40. Stenton G.R., Kim M.K., Nohara O., Chen C.F., Hirji N., Wills F.L., et al. Aerosolized Syk antisense suppresses Syk expression, mediator release from macrophages, and pulmonary inflammation. J Immunol 164 (2000) 3790-3797
41. Stenton G.R., Ulanova M., Dery R.E., Merani S., Kim M.K., Gilchrist M., et al. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol 169 (2002) 1028-1036
42. Popescu F.D. Antisense- and RNA interference-based therapeutic strategies in allergy. J Cell Mol Med 9 (2005) 840-853
43. Lai J.Y., Cox P.J., Patel R., Sadiq S., Aldous D.J., Thurairatnam S., et al. Potent small molecule inhibitors of spleen tyrosine kinase (Syk). Bioorg Med Chem Lett 13 (2003) 3111-3114
44. Blease K. Targeting kinases in asthma. Expert Opin Investig Drugs 14 (2005) 1213-1220
45. Cywin C.L., Zhao B.P., McNeil D.W., Hrapchak M., Prokopowicz A.S., Goldberg D.R., et al. Discovery and SAR of novel Naphthyridines as potent inhibitors of spleen tyrosine kinase (SYK). Bioorg Med Chem Lett 13 (2003) 1415-1418
46. Hisamichi H., Naito R., Toyoshima A., Kawano N., Ichikawa A., Orita A., et al. Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives. Bioorg Med Chem 13 (2005) 4936-4951
47. Yamamoto N., Takeshita K., Shichijo M., Kokubo T., Sato M., Nakashima K., et al. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther 306 (2003) 1174-1181
48. Fabian M.A., Biggs III W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23 (2005) 329-336
49. Rossi A.B., Herlaar E., Braselmann S., Huynh S., Taylor V., Frances R., et al. Identification of the Syk kinase inhibitor R112 by a human mast cell screen. J Allergy Clin Immunol 118 (2006) 749-755
50. Guyer B., Shimamoto S., Bradhurst A., Grossbard E., Dreskin S., and Nelson H.S. The effect of a novel inihibitor of mast cell activation on mediators, symptoms and nasal patency in allergic rhinitis. J Allergy Clin Immunol 113 (2004) S28-S29
51. Doyle W.J., Boehm S., and Skoner D.P. Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy. J Allergy Clin Immunol 86 (1990) 924-935
52. Meltzer E.O., Berkowitz R.B., and Grossbard E.B. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 115 (2005) 791-796
53. Matsubara S., Koya T., Takeda K., Joetham A., Miyahara N., Pine P., et al. Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol 34 (2006) 426-433
54. Matsubara S., Li G., Takeda K., Loader J.E., Pine P., Masuda E.S., et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 173 (2006) 56-63